Patent ID: 9005099
Filing Date: 2015-04-14
Classification: A61F,A61K,A61N,A61P

Abstract:
1. A method of treating progressive myopia comprising: providing an apparatus that upon insertion will deliver a drug formulation comprising riboflavin to scleral ocular tissue of a sclera of an eye of a patient in need of treatment for progressive myopia; inserting the apparatus through an opening in a conjunctiva to deliver to deliver the drug formulation to targeted regions of the scleral ocular tissue; and allowing the drug formulation to diffuse from the apparatus into the targeted regions of the scleral tissue to soak the scleral tissue, wherein the apparatus is disposed in and delivers the drug formulation to an equatorial region of the sclera beneath the rectus muscles and the four quadrants of the sclera between the rectus muscles, wherein the drug formulation comprises riboflavin capable of being activated by UVA radiation for purposes of inducing cross-linking of scleral collagen tissue, and wherein the crosslinking imparts and increase in biomechanical rigidity or stiffness to the treated ocular tissue to reduce, limit, and/or arrest elongation of the eye that is characteristic of the progressive myopia.